Russian Scientists Develop New Cancer Vaccine, Ready for Clinical Use
Moscow, – Russian scientists have announced the development of a new cancer vaccine, which is now ready for clinical application, according to the country’s Federal Medical-Biological Agency (FMBA). The announcement was made by FMBA head Veronika Skvortsova at the Eastern Economic Forum, Russian news agency TASS reported. The vaccine, named Enteromix, is based on mRNA…
Moscow, – Russian scientists have announced the development of a new cancer vaccine, which is now ready for clinical application, according to the country’s Federal Medical-Biological Agency (FMBA).
The announcement was made by FMBA head Veronika Skvortsova at the Eastern Economic Forum, Russian news agency TASS reported.
The vaccine, named Enteromix, is based on mRNA technology – the same platform used in several COVID-19 vaccines. Unlike traditional vaccines that employ weakened viruses, this method trains the body’s cells to produce specific proteins that trigger the immune system to target and attack cancer cells.
Researchers spent several years developing the vaccine, including three years of pre-clinical trials. The results showed the vaccine to be safe, even with repeated use, and in some cancer cases, it reduced tumor growth by 60 to 80 percent or significantly slowed its progression.
The development marks a significant step in cancer immunotherapy, with scientists hopeful that clinical use could expand treatment options for patients in the coming years.
